Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
Status:
Completed
Trial end date:
2019-11-05
Target enrollment:
Participant gender:
Summary
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy
and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM study")